Venture Life Group PLC (LSE:VLG) reported continuing Revenue of £50.0m for an extended 17-month period, after selling its Manufacturing operations and oral care brands. The consumer healthcare group also announced that founder Jerry Randall will step down as chief executive, with chief financial officer Daniel Wells succeeding him from 1 January 2027.

What was announced

Venture Life published final results for the 17 months ended 31 May 2026, following a change in its accounting reference date from 31 December to 31 May. The comparative figures are for the 12 months to 31 December 2024, so the headline numbers are not like-for-like.

Revenue from continuing operations was £50.0m (2024: £26.6m). The company reported underlying growth of 16.0% on a proforma basis against the previous 17 months to 31 May 2025, made up of 14.8% from Volume and 1.2% from price. UK revenue was £31.9m (£16.2m) and US revenue £3.0m (£0.6m). Its largest brands over the period were Balance Activ (£12.2m), Lift (£11.0m), Health & Her (£10.7m) and Earol (£8.2m).

The numbers

For continuing operations:

  • Gross profit of £22.3m (£12.2m), a gross Margin of 44.6% (45.8%)
  • Adjusted EBITDA of £7.9m (£6.2m), a margin of 15.7% (23.2%)
  • Loss before tax of £4.0m (2024: nil)
  • Adjusted diluted EPS of 5.80p (3.11p) and a diluted loss per share of 2.98p (0.02p)

The company attributed the lower margin to a temporary de-leveraging of its operating cost base after the disposals and to higher Investment in technology, organisational capability and marketing, which rose to 9.4% of revenue from 6.1%.

Including discontinued operations, which contributed a profit of £7.2m, group profit after tax was £3.4m (2024: loss of £0.3m). Group diluted EPS was 2.70p (loss of 0.25p) and group adjusted diluted EPS 14.74p (3.65p). No Dividend was disclosed.

Cash was £11.5m at 31 May 2026 with no drawn debt, compared with net Debt of £18.7m at the end of 2024. The group has an undrawn £30m revolving Credit Facility and a £20m accordion, extended to March 2028. It returned £7.1m through share buybacks, repurchasing 10.6m shares at an average of 67.3p.

Disposals and acquisition

In July 2025 Venture Life sold its CDMO development and manufacturing operations in Italy and Sweden, together with certain non-core products, to BioDue S.p.A at an Enterprise value of €62m, recording a net disposal gain of £11.7m. In December 2025 it sold the Dentyl and Ultradex oral care brands for an enterprise value of up to £4.5m.

After the period end, on 2 June 2026, it completed the Acquisition of the FemiClear and CUROXEN brands for initial consideration of $23.0m, plus up to $5.0m contingent on performance in the 12 months to 31 December 2026. The company expects the brands to generate about $14m of net revenue in 2026, and the deal brings a US sales and Marketing team.

CEO succession and outlook

Jerry Randall, who founded the Business 16 years ago, will step down as chief executive on 31 December 2026 and remain an executive director until 31 May 2027, after which he will advise the board and senior management. Daniel Wells, who joined through the BBI Healthcare acquisition in 2021, becomes chief executive on 1 January 2027. The board, chaired by Paul McGreevy, is searching for a new chief financial officer.

The board said it is "highly confident in meeting market expectations for the year ending 31 May 2027 and beyond". It also stated an aspiration "to achieve annual revenue in excess of £300 million within the next five years", at which scale it expects an adjusted EBITDA margin of about 25%. These are the company's targets. Near-term priorities include integrating FemiClear and CUROXEN, organic growth from its main brands and selective acquisitions.